Soleus Capital — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers.
BiotechDigital HealthMedical DevicesDoylestown, US
John P. Hamill(Executive Officer)inOren Gilad(Chief Executive Officer, President)in
BoardJean-Pierre Bizzari(Director)Gabriela Gruia(Director)Rifat Pamukcu(Director)Bernd Seizinger(Director)
Co-investors5AM VenturesHealthCapRobin Hood VenturesRosetta Capital Ltd.Versant Ventures
Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.
BiotechDeep TechHealthtechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Chief Financial Officer and Chief Business Officer)inCatherine Priest(Chief Development Officer)inGautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)
Co-investorsBerkeley FrontierIaso VenturesThe Column GroupViking GlobalYsios CapitalAlexandria+8 more
Pillar Biosciences develops kitted next-generation sequencing (NGS) panels and its SLIMamp single-tube library preparation technology for clinical and research laboratories, focused on cancer diagnostics.
BiotechDigital HealthHealthtechMedical DevicesNatick, US
Shawn Liu(Director)Hui Yang(Director)Gang Song(Executive Officer, Director)Zhaohui Wang(Director)Robert Forrester(Director)inHong Fang Song(Director)
Co-investorsCatalio Capital Management, LPHB VenturesBain Capital Life Sciences
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Timothy A. Springer(Co-Founder)Andrew C. Kruse(Director)Alise Reicin(Executive Officer, Director)inDaniel Lochner(Executive Officer)Marc Schwabish(Executive Officer)inPeter McNamara(Executive Officer)in
Co-investorsEcoR1 CapitalVida VenturesAlly Bridge GroupClarus VenturesFarallon EquitiesPolaris Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.



















